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http://www.biomedcentral.com/1741-7007/11/122RESEARCH ARTICLE Open AccessIpsA, a novel LacI-type regulator, is required for
inositol-derived lipid formation in Corynebacteria
and Mycobacteria
Meike Baumgart1, Kerstin Luder1, Shipra Grover2, Cornelia Gätgens1, Gurdyal S Besra2 and Julia Frunzke1*Abstract
Background: The development of new drugs against tuberculosis and diphtheria is focused on disrupting the
biogenesis of the cell wall, the unique architecture of which confers resistance against current therapies. The
enzymatic pathways involved in the synthesis of the cell wall by these pathogens are well understood, but the
underlying regulatory mechanisms are largely unknown.
Results: Here, we characterize IpsA, a LacI-type transcriptional regulator conserved among Mycobacteria and
Corynebacteria that plays a role in the regulation of cell wall biogenesis. IpsA triggers myo-inositol formation by
activating ino1, which encodes inositol phosphate synthase. An ipsA deletion mutant of Corynebacterium
glutamicum cultured on glucose displayed significantly impaired growth and presented an elongated cell
morphology. Further studies revealed the absence of inositol-derived lipids in the cell wall and a complete loss of
mycothiol biosynthesis. The phenotype of the C. glutamicum ipsA deletion mutant was complemented to different
extend by homologs from Corynebacterium diphtheriae (dip1969) and Mycobacterium tuberculosis (rv3575), indicating
the conserved function of IpsA in the pathogenic species. Additional targets of IpsA with putative functions in cell
wall biogenesis were identified and IpsA was shown to bind to a conserved palindromic motif within the
corresponding promoter regions. Myo-inositol was identified as an effector of IpsA, causing the dissociation of the
IpsA-DNA complex in vitro.
Conclusions: This characterization of IpsA function and of its regulon sheds light on the complex transcriptional
control of cell wall biogenesis in the mycolata taxon and generates novel targets for drug development.
Keywords: Transcriptional regulator, Corynebacterium glutamicum, Corynebacterium diphtheriae, Mycobacterium
tuberculosis, Cell wall synthesis, Mycolic acids, Mycothiol, Inositol, LM, LAMBackground
The human pathogens Mycobacterium tuberculosis and
Corynebacterium diphtheriae, as well as many related spe-
cies of the order Corynebacteriales, share a distinctive cell
wall architecture that plays an important role in virulence
and imparts effective protection against harsh environmen-
tal conditions and resistance to therapies [1]. One unique
feature of these cell walls is the presence of long-chain
α-alkyl, β-hydroxy fatty acids, called mycolic acids, which
form a second bilayer close to the cell surface that is simi-
lar to the outer membrane of Gram-negative bacteria [2].* Correspondence: j.frunzke@fz-juelich.de
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stated.The enzymes and regulatory mechanisms involved in bio-
synthesis of the cell walls are primary targets for the devel-
opment of new drugs.
A great deal is known about these bacterial cell walls
(Figure 1A). The plasma membranes are rich in phospho-
lipids, such as phosphatidylglycerol, diphosphatidylglycerol
and phosphatidylinositol (PI). While inositol is an essential
polyol in eukaryotes, in eubacteria it is present only in the
order Corynebacteriales where it serves both as a cell wall
component and as a building block of mycothiol (MSH),
the major antioxidant in Mycobacteria, similar to glutathi-
one [3]. One function of PI is to anchor cell wall lipogly-
cans, specifically PI mannosides (PIMs), lipomannan (LM)
and liporarabinomannan (LAM), to the plasma membraneral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 IpsA plays an essential role in the integrity of the cell wall of Corynebacteriales. (A) Current model of the structure of the cell wall
of Corynebacteria and Mycobacteria. (B) Comparison of the organization of the IpsA genome locus in C. glutamicum and related species. IpsA and
homologous proteins are shown in black. Data were taken from [5,6]. The percentage identity of the amino acid sequences to IpsA from C.
glutamicum was taken from NCBI Blast. hp, hypothetical protein. (C, D) Growth curves (C) and phenotype (D) of C. glutamicum wild-type and
ΔipsA. Results in (C) show the growth (backscatter) from sequential cultures in minimal medium with glucose or myo-inositol as carbon source.
After reaching the stationary phase, the cells were diluted into fresh medium at an initial OD600 of 1. Shown are three glucose cultures and the
third myo-inositol culture (n = 3). In (D), DNA was stained with 4’,6-diamidino-2-phenylindole (DAPI) (cyan) and lipophilic regions with nile red
(red). The scale bar is 5 μm.
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steps in the following order: PI→PIM→LM→LAM.
In Mycobacteria, there is a three-step process for syn-
thesis of PI. Step 1 is cyclization of glucose-6-phosphate to
1D-myo-inositol-3-phosphate, a reaction that is catalyzed
by a myo-inositol phosphate synthase, Ino1 (Rv0046c) [7].
In step 2, the 1D-myo-inositol-3-phosphate is dephosphor-
ylated by inositol monophosphatase (IMP) [8] to yield
myo-inositol. Step 3 is the transfer of diacylglycerol (DAG)
from cytidine diphosphate-diacylglycerol (CDP-DAG) to
myo-inositol by a PI synthase, PgsA (Rv2612c) [9]. The
enzymes Ino1 and PgsA are essential for the viability of
Mycobacteria [10,11]. An ino1 mutant of M. tuberculosis
grows in vitro only in the presence of high inositol con-
centrations and was no longer able to kill SCID mice (see
Movahedzadeh et al., [10]). In Mycobacterium smegmatis,
ino1 has been shown to be essential for growth in theabsence of exogenous inositol [12]. Ino1 has therefore
been proposed as a target for the development of new
antibiotics [10,13].
In contrast to the wealth of knowledge about the bio-
genesis of cell walls, little is known about the regulatory
circuits that control these processes [4]. IpsA was
chosen as target for further studies from a set of mu-
tants strains as a ΔipsA mutant displayed a drastically al-
tered cell morphology hinting towards a function in the
control of cell wall biosynthesis. The catabolism of myo-
inositol has been examined in C. glutamicum [14,15] but
regulation of myo-inositol formation has not been deeply
investigated up until now. Here, a regulator of inositol
synthesis in the model organism C. glutamicum is de-
scribed. Named IpsA, it is a novel LacI-type regulator
that acts as an inositol-dependent transcriptional activa-
tor of the myo-inositol phosphate synthase gene. IpsA
Figure 2 Complementation of the ΔipsA phenotype with ipsA
and the target gene ino1 (cg3323). For chromosomal
complementation, the gene ipsA was integrated into the intergenic
region of cg1121 to cg1122 under control of the native promoter.
(A) Growth of the strains in CGXII minimal medium with 2% (w/v)
glucose as carbon source. The average and standard deviation of
three biological replicates is shown. (B) Fluorescence microscopy
images of stationary phase cells of the cultures presented in (A). (C)
Plasmid-based complementation with the target gene ino1 (cg3323).
The strains were cultivated in CGXII minimal medium with 2% (w/v)
glucose and 50 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) for
induction of ino1 expression.
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Mycobacteria, including the prominent pathogenic species
C. diphtheriae and M. tuberculosis.
Results
IpsA is a novel LacI-type regulator conserved in the
Corynebacteriales
IpsA was assigned by homology to the LacI family of
transcriptional regulators, which often coordinate the
available nutrients with the expression of catabolic genes
[16]. The corresponding genomic loci display a remark-
able level of conservation across the Corynebacteriales
(Figure 1B). In previous studies, the structure of IpsA
(Cg2910) was analyzed (PDB:3H5T); its physiological
function is the subject of this study.
IpsA deletion affects cell shape and growth
To gain insight into the function and possible target
genes of IpsA, an in-frame deletion mutant was con-
structed. Growth rates and final backscatter of ΔipsA
cells were significantly below control levels using min-
imal medium with glucose as carbon source, and these
shortfalls increased in magnitude with successive subcul-
tivation (Figure 1C). The morphology of the mutant
strain was altered, as revealed by fluorescence micros-
copy with staining of DNA (4’,6-diamidino-2-phenylin-
dole (DAPI)) and membranes (nile red). ΔipsA cells
formed chain-like structures and failed to divide prop-
erly. DNA in the cells was unevenly distributed and was
frequently found in the extracellular space, indicative of
severe damage to the cell membrane and/or the cell wall
(Figure 1D, for a larger sample see Additional file 1:
Figure S1). Membrane staining revealed several intact
cell septa in the unshaped mutant cells.
Both the growth defect and altered morphology could
be partially overcome by plasmid-encoded ipsA under
control of the native or an inducible promoter (data not
shown). These efforts revealed that increased levels of
IpsA also affect growth of C. glutamicum. Full restor-
ation of the wild-type phenotype was only achieved
when ipsA was reintegrated into the mutant strain
(intergenic region cg1121 to cg1122) and expressed from
its native promoter (Figure 2A, B). When the cells were
cultivated with myo-inositol instead of glucose as carbon
source, no differences were observed between the wild-
type and ΔipsA strains in terms of growth and morph-
ology (Figure 1C, D).
The impact of ipsA mutation on transcription
To elucidate the transcriptional changes caused by the
deletion of ipsA, DNA microarray experiments were
performed. More than 450 genes showed alterations in
mRNA level greater than a factor of 2, using cells in the
exponential growth phase (OD600 = 5) cultivated in minimal
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Table S3, full data deposited in GEO database [17] under
accession number GSE50210).
The expression of the gene cg3323, which encodes a
myo-inositol phosphate synthase (ino1), and of the op-
eron (cg0044 to cg0046), which encodes an uncharacter-
ized ABC transporter, was reduced by more than a
factor of ten in the mutant strain (Table 1). Other down-
regulated genes included a flavin-containing monooxy-
genase (cg3195), a hypothetical endoglucanase (cg2896),
and two further transporters (cg0621 to cg0623 and
cg2181 to cg2184) (Additional file 1: Table S3). Among
the strongly upregulated genes was a cluster encoding
enzymes for inositol catabolism (cg3389 to cg3392), an
operon encoding both menE and a putative integral
membrane protein (cg0533 to cg0534), and a putative
dinucleotide-binding enzyme (cg1421). Many of the
affected genes are components of the DtxR stimulon,
which plays a central role in iron homeostasis in C.
glutamicum [18,19]. We speculate that these changes
are the result of an impaired iron uptake of the mutant
strain due to the defects in the cell wall. In combination
with the observed growth phenotype of the mutant
strain, the alterations in gene expression indicate that
IpsA is a major regulator of inositol-derived cell wall
components.
Identification of direct IpsA target promoters
The microarray experiments revealed several putative
target genes of IpsA. To determine whether these genes
are directly regulated by IpsA, the promoter regions of




Gene Annotated function Ratio
cg3323 ino1 Myo-inositol phosphate synthase 0.047
cg0044 rbsB ABC transporter/periplasmic D-ribose-binding
protein
0.082
cg0045 - Probable ABC transport protein, membrane
component
0.138
cg2910 - Transcriptional regulator, LacI family 0.173
cg3195 - Flavin-containing monooxygenase 0.178
cg0046 - Probable ABC transport protein, ATP-binding
component
0.323
cg3210 - Cell envelope-related transcriptional regulator 0.411
cg1421 - Putative dinucleotide-binding enzyme 5.214
cg0533 menE O-succinylbenzoic acid-CoA ligase 5.467
cg0534 - Putative integral membrane protein 5.597
mRNA ratios (ΔipsA/wild-type) of IpsA target genes in microarray experiments
are shown. Presented are all genes where binding of IpsA could be shown in
electrophoretic mobility shift assays (EMSAs) as well as IpsA itself, confirming
the deletion.mobility shift assays (EMSAs) for the formation of com-
plexes with purified IpsA protein. We analyzed the pro-
moters of all genes that were more than fourfold
regulated but excluded ribosomal proteins and genes
belonging to the DtxR/RipA regulon. DNA fragments
(approximately 500 bp) covering the promoter regions
of putative target genes, were incubated with increasing
IpsA-His concentrations. IpsA-His bound with high
affinity to the promoter regions of cg0044 and ino1
(cg3323) and with lower affinity to the promoter regions
of cg0534 (a putative integral membrane protein),
cg1421 (a putative dinucleotide binding enzyme), cg1476
(thiC, thiamine biosynthesis protein ThiC), cg1918 (a
putative secreted protein), and cg3195 (flavin containing
monooxygenase) (Figure 3; all tested fragments are
shown in Additional file 1: Figure S3).
Determination of the IpsA DNA binding site
Using EMSAs, two separate binding sites were identified
in the promoter of ino1 and one in the promoter of
cg0044 (Figure 3A and Additional file 1: Figure S4). Ana-
lysis of these sites using the motif-based sequence analysis
tool MEME [20] revealed a conserved palindromic motif,
which was subsequently verified by mutational analysis
(Figure 4). In particular, the central six base pairs appear
to be crucial for IpsA binding. The preliminary motif was
used to search for further binding sites in putative target
genes and across the genome of C. glutamicum. Binding
sites were identified by EMSAs using oligonucleotides in
the promoters of cg1421, cg3195, cg3210 and cg0534
(Table 1, Figure 3A and Additional file 1: Figure S5). The
identified motifs were used to define the IpsA consensus
motif shown in Figure 3C.
Myo-inositol is an effector molecule of IpsA
The enzyme encoded by the main IpsA target gene is
Ino1, a myo-inositol phosphate synthase that catalyzes the
formation of 1D-myo-inositol-3-phosphate from glucose-
6-phosphate [7]. We tested several metabolites involved
in the relevant pathway for their influence on the forma-
tion of the IpsA-DNA complex. A clear backshift was
observed for myo-inositol but not for 1D-myo-inositol-
1-phosphate, 1D-myo-inositol-3-phosphate or glucose-6-
phosphate (Figure 3B). The effect of myo-inositol could be
observed at concentrations down to 0.2 mM (Additional
file 1: Figure S6). This effect is specific for IpsA DNA bind-
ing, as the addition of up to 50 mM myo-inositol did not
have any effect on the formation of an unrelated protein-
DNA complex (for example, AcnR and the acn promoter,
Additional file 1: Figure S7).
IpsA is required for inositol-dependent regulation of ino1
The major function of IpsA revealed thus far is the acti-
vation of ino1 in the absence of external inositol.
Figure 3 Target genes, effector and binding sites of IpsA. (A) Binding of IpsA to 30 bp oligonucleotides covering the binding sites in the
putative target promoters. As negative control the oligonucleotide cg3323-d (sequence AGGTCTGATTTCTGCTGGGAATCCCCACAT) was used,
which is located immediately downstream of the IpsA binding sites in the cg3323 promoter. (B) The influence of intermediates in inositol
metabolism (5 mM each) on the binding of IpsA to the ino1 promoter. myo-I, myo-inositol; I1P, 1D-myo-inositol-1-phosphate; I3P, 1D-myo-inositol-
3-phosphate; G6P, glucose-6-phosphate. (C) The IpsA consensus motif predicted by MEME [20] and an overview of the sites in the corresponding
promoter regions. (D) Promoter-fusion studies using the promoter of ino1 fused to eyfp (pJC1-Pcg3323-eyfp). The specific fluorescence of ATCC
13032 containing this plasmid on glucose was set to 1 and the other values were calculated accordingly.
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the ΔipsA strain is complemented by the constitutive ex-
pression of ino1 under standard conditions (Figure 2C).
To study the influence of IpsA and myo-inositol on the
expression of ino1 in vivo, we fused the ino1 promoter
to eyfp (enhanced yellow fluorescent protein) and moni-
tored the fluorescence output of the wild-type and the
ΔipsA strain during growth on glucose and myo-inositol
(Figure 3D). Strong promoter activity was observed in
the wild-type during growth on glucose. Expression of
eyfp was significantly decreased in the ipsA deletion
strain and was lower still when either strain was culti-
vated with myo-inositol as the carbon source.
IpsA function is conserved in C. diphtheriae and M.
tuberculosis
The conservation of IpsA in the Corynebacteriales sug-
gests that it may play a similar role in pathogenic relatives.
To assess this possibility, we tested in vivo complementa-
tion of C. glutamicum ΔipsA with the IpsA homologs of
M. tuberculosis (Rv3575) and C. diphtheriae (DIP1969).
Partial complementation of growth and morphology was
achieved (Figure 5A-C). Growth was still slightly retarded
but the final OD was significantly increased in comparison
with the ΔipsA strain. Likewise, the morphological pheno-
type of the complemented strains fell in between the wild-
type and the ΔipsA strain, with a slightly better comple-
mentation by DIP1969 compared to Rv3575. Most cellsdisplayed the wild-type morphology and, while some
chain-like cell clusters were observed (Figure 5C), these
were shorter than clusters of the ΔipsA strain (Figure 1D).
We also tested the binding of IpsA to the promoter
regions of C. diphtheriae and M. tuberculosis homologs of
cg3323 and cg0044 using EMSAs (Figure 5D). C. glutami-
cum IpsA bound strongly to the C. diphtheriae promoters
DIP0115 and DIP0021 and the binding sites were deter-
mined (Figure 5E and Additional file 1: Figure S8). In M.
tuberculosis, Rv0046c is organized in an operon with
Rv0047c. A binding site was identified within the open
reading frame (ORF) of Rv0047c, suggesting the occur-
rence of a second promoter upstream of ino1 (Figure 5E).
Mycothiol synthesis is abolished in C. glutamicum ΔipsA
Besides being a precursor of PI and derived lipids, myo-
inositol is one of the building blocks of mycothiol, the
major antioxidant of Corynebacteria and Mycobacteria.
Therefore, we measured mycothiol in a set of our strains
(Figure 6) using a method previously published for C.
glutamicum [21]. The mycothiol peak was identified by
comparison of wild-type chromatograms with those of a
mutant depleted in mycothiol synthesis (ΔmshC). To
proof that the corresponding peak, lacking in ΔmshC,
represents mycothiol, thiols were blocked with NMM
(N-methyl-maleimide) prior to derivatization with bro-
mobimane. In this sample, the largest peak of the wild-
type at 5.6 minutes was indeed absent the two control
Figure 4 Mutational analysis of one of the IpsA binding sites in the ino1 promoter. The importance of the predicted DNA sequence motif
for IpsA binding was tested in electrophoretic mobility shift assays (EMSAs) with DNA fragments in which three nucleotides of the proposed
motif were exchanged, as indicated. A + indicates that the mutated fragment was bound with the same affinity as the unaltered wild-type
fragment (positive control); (+) indicates that the mutated fragment was shifted, but with lower affinity; - indicates that the mutated fragment
was not shifted. In the case of M3 and M4, binding was completely abolished by the mutation, indicating that the six central base pairs are crucial
for IpsA binding. For M1, M2 and M6 a slight decrease of binding was observed. The binding of M5 was unchanged.
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ΔipsA strain but could fully be restored by plasmid-
based expression of ipsA (Figure 6). Interestingly, the
mycothiol measurements showed a partial complemen-
tation with the ipsA homologs from C. diphtheriae and
M. tuberculosis, which is in line with our previous
findings regarding growth and morphology of cross-
complemented strains (Figure 5).
PI-based glycolipid synthesis is lost in C. glutamicum
ΔipsA
To study the effect of IpsA on the formation of PI-based
phosphoglycolipids, [14C]-labeled polar lipids were ex-
tracted from wild-type and ΔipsA C. glutamicum. Theglycolipid profiles were examined using two-dimensional
thin-layer chromatography (2D-TLC) (Figure 7). The
wild-type strain showed presence of AcPIM2, PI, Gl-A
(GlcAGroAc2) and Gl-X (ManGlcAGroAc2) in lipid
extracts as compared to known standards and previous
studies [22], isolated from the cells grown with either
myo-inositol or glucose. Under normal conditions, C.
glutamicum produces both PI and Gl-X, which is an al-
ternative glycolipid anchor to PI for synthesis of Cg-LM.
The glycolipid Gl-X is derived from Gl-A, its precursor
product. Although both PI and Gl-X can be visualized
on TLC analysis, the formation of Gl-X is distinguished
only in the case of mutants lacking PI, as both Gl-X and
PI do not separate out as distinct spots [23,24]. However,
Figure 5 IpsA in Corynebacterium diphtheriae and Mycobacterium tuberculosis. Corynebacterium glutamicum ΔipsA carrying the plasmids
pAN6, pAN6-DIP1969 or pAN6-rv3573 and C. glutamicum wild-type with pAN6 as control were cultivated in CGXII with glucose without isopropyl
β-D-1-thiogalactopyranoside (IPTG) (A) or with 50 μM IPTG (B). (C) Microscopic phenotypes of the complemented strains. DNA was stained with
4’,6-diamidino-2-phenylindole (DAPI) (cyan) and lipophilic regions with nile red (red), scale bar 5 μm. (D) Oligonucleotides (30 bp, 1 μM for
DIP0021 and DIP0115, 0.5 μM for Rv0047 and the negative control) covering the predicted binding sites in the promoter regions of the respective
genes were incubated with IpsA at the given concentrations and analyzed on 15% native polyacrylamide gels. In M. tuberculosis, Rv0046 is
organized in an operon with Rv0047. A binding site was identified within the open reading frame (ORF) of Rv0047, suggesting the occurrence of
a second promoter upstream of ino1. (E) IpsA binding motif derived from the high affinity C. glutamicum targets and the C. diphtheriae and M.
tuberculosis binding sites.
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both wild-type and mutant strains. For convenience, the
TLC results for polar lipid extracts from the ipsAmutant defective in PI synthesis have been marked to
depict Gl-X at the same position at which PI is depicted
in the wild-type and complemented strains. The labeling
Figure 6 Determination of mycothiol production in
Corynebacterium glutamicum wild-type and different mutants
and complemented strains. The mycothiol was derivatized
using bromobimane, separated by high-performance liquid
chromatography (HPLC) and monitored using a fluorescence
detector (390 nm excitation and 475 nm emission). As control, the
mycothiol deficient strain ΔmshC was used as well as a wild-type
sample that had been treated with N-methyl-maleimide (NMM) to
block thiols prior to derivatization. The peak assumed to be
mycothiol is marked with a dotted line. Presented is a representative
chromatogram of three biological replicates each.
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absence of AcPIM2 was observed in lipid extracts isolated
from C. glutamicum ΔipsA when cultured in minimal
media supplemented with glucose indicating the loss of
PI-based glycolipid synthesis in the mutant (Figure 7B).
The lipid profiles of complemented strains C. glutamicumΔipsA::pK18-ipsA and C. glutamicum ΔipsA harboring
cg3323 and DIP1969 in plasmid pAN6, were identical to
the wild-type when grown on glucose, demonstrating suc-
cessful complementation of the loss of gene function in
these strains (Figure 7C-E). However, the lipid extracts
from C. glutamicum ΔipsA harboring Rv3575 in plasmid
pAN6 cultured under the same conditions displayed no
complementation as none of the components was stained
with phosphate stain (results not shown). The lipid ex-
tracts isolated from the mutant and complemented strains
cultured in minimal media supplemented with myo-inositol
were similar to wild-type, with distinct AcPIM2 and PI
production (Figure 7G, H and Additional file 1: Figure S9).
Analysis of lipoglycan extracts
Since the lipoglycans LM and LAM are built on PIMs
which are mannosylated products of PI, the effect of IpsA
was also studied on these lipoglycans extracted from the
wild-type, C. glutamicum ΔipsA and the complemented
strains (Additional file 1: Figure S10A). LAM and Cg-LM-
A/B were clearly present in extracts from the wild-type
cultured in glucose or myo-inositol. However, the lipogly-
can extracts from the mutant C. glutamicum ΔipsA grown
on glucose revealed no LAM while a band corresponding
to Cg-LM-B could be observed. On glucose the comple-
mented strains C. glutamicum ΔipsA::pK18-ipsA and C.
glutamicum ΔipsA containing plasmid encoded Cg3323
and DIP1969 exhibited lipoglycan profiles identical to the
wild-type as distinct bands corresponding to both LAM
and Cg-LM-A/B. However, no band corresponding to
LAM was observed in lipoglycan extracts of C. glutamicum
ΔipsA complemented with Rv3575c in pAN6 plasmid
grown in minimal media supplemented with glucose.
Instead, a band corresponding to Cg-LM-B was evident.
The lipoglycan extracts isolated from the mutant and com-
plemented strains cultured in minimal media supplemented
with myo-inositol were similar to wild-type with distinct
LM and LAM (Additional file 1: Figure S10B).
Discussion
The metabolic pathways for biogenesis of the cell wall in
Mycobacteria and Corynebacteria are well characterized,
with few gaps remaining to be filled. In contrast, the
regulation of these processes remains largely undiscov-
ered. Here, we describe the novel transcriptional regula-
tor IpsA, which functions as an activator of ino1 and
other target genes most likely involved in the synthesis
of inositol-derived cell wall components and mycothiol
(MSH) in Corynebacteria and Mycobacteria (Figure 8).
Myo-inositol was shown to act as effector of IpsA and
our studies are consistent with a conserved function for
this regulator throughout the Corynebacteriales.
The polyol myo-inositol has an important function in
Mycobacteria and Corynebacteria: it serves as the key
Figure 7 Two-dimensional thin-layer chromatography (2D-TLC)
analysis of [14C]-labeled polar lipids from Corynebacterium
glutamicum cells grown in glucose (A-F) or myo-inositol (G-H).
(A) and (G) C. glutamicum ATCC 13032, (B) and (H) ATCC 13032
ΔipsA, (C) ATCC 13032 ΔipsA pAN6-cg3323, (D) ATCC 13032 ΔipsA::
pK18int-ipsA, (E) ATCC 13032 ΔipsA pAN6-DIP1969 and (F) ATCC
13032 ΔipsA pAN6-Rv3575. The cells were cultured in CGXII with
either glucose (A-F) or myo-inositol (G, H). PI, phosphatidylinositol;
TMCM, trehalose monocorynomycolate; GMCM, glucose monocory-
nomycolate; Ac1PIM2, monoacylated phosphatidyl myo-inositol
dimannoside; GlcAGroAc2, 1,2-di-O-C16/C18:1-(α-D-glucopyranosyluronic
acid)-(1→3)-glycerol (GL-A); ManGlcAGroAc2 1,2-di-O-C16/C18:1
-(α-D-mannopyranosyl)-(1→4)-(α-D-glucopyranosyluronic acid)-
(1→3)-glycerol (GL-X).
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as well as for the antioxidant MSH [1,3]. Several studies
have illustrated the potential of the underlying biosyn-
thetic pathways as putative drug targets [13]. For ex-
ample, an ino1 mutant of M. tuberculosis can only grow
in the presence of high concentrations of myo-inositol
[10] and a M. tuberculosis mutant defective in MSH bio-
synthesis requires catalase for growth on plates [25].
Our studies have shown that the deletion of ipsA leads
to a complete loss of mycothiol biosynthesis, demon-
strating the importance of IpsA also for this metabolic
pathway.
Myo-inositol and its phosphate derivatives are com-
mon substances in eukaryotes and are therefore present
in significant quantities in the natural habitats of M.
tuberculosis, C. diphtheriae (the human body) and C.
glutamicum (soil) [26]. It has been shown that myo-
inositol can be used by C. glutamicum as a carbon and
energy source, and several transporters, enzymes and
regulators of the catabolic pathway have been identified
[14,15]. In the present study, microarray analysis re-
vealed that the two main target genes of IpsA, ino1 and
cg0044, are strongly downregulated during growth on
inositol compared to growth on glucose, which is in line
with IpsA being an inositol-dependent activator of both
genes/operons [14].
Bioinformatic analysis of ipsA and its homologs in
other Corynebacteria and Mycobacteria revealed conser-
vation of the gene among these species (Figure 1B). In
many genomes of the Corynebacteriales, ipsA is located
next to znuACB, which encodes a putative zinc transport
system regulated by Zur [27]. Furthermore, genes in-
volved in the biosynthesis of trehalose (otsAB), which is
also an important component of the cell wall of the
Corynebacteriales, are frequently located downstream of
ipsA, but their orientations are divergent [28,29]. The
product of the main target gene of IpsA, Ino1, contains
a zinc ion in its catalytic center and needs NAD+ for its
reaction [30].
The transcriptional organization of ino1 differs be-
tween Corynebacteria and Mycobacteria. While ino1 is
the only gene in the transcriptional unit in Corynebac-
teria, it is cotranscribed with a preceded, uncharacter-
ized PadR-like transcriptional regulator in Mycobacteria
[31] (Additional file 1: Figure S11). Given the genomic
organization, we suspect that this regulator is an add-
itional player in the control of ino1 expression.
That ino1 is the main target gene of IpsA is supported
by the observation that the ipsA phenotype was comple-
mented by overexpression of ino1. One could assume
that this is the only real target gene of IpsA, but it is not
unlikely, that other target genes only appear to be im-
portant under different conditions, for example, another
carbon source or certain stress conditions. Based on DNA
Figure 8 Model of IpsA function. In Corynebacteria and Mycobacteria, myo-inositol (mIno) is an important building block for cell wall
components and mycothiol. mIno can be taken up from the culture medium or synthesized from glucose-6-phosphate (G6P) via 1D-myo-inositol-
3-phosphate (I3P). When mIno concentration is low, IpsA activates ino1, encoding myo-inositol phosphate synthase, which catalyzes the formation
of I3P from G6P. Besides ino1, IpsA activates or represses several other targets of unknown function.
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target genes of IpsA, all of which were previously unchar-
acterized. The operon cg0044 to cg0046 encodes an ABC
transporter of unknown function. It may be involved in
the uptake of inositol(-derived) carbohydrates required for
cell wall biogenesis. The product of cg3210 is annotated as
a cell envelope-related transcriptional regulator of the
LytR type. It has a transmembrane domain and is con-
served in Corynebacteria and Mycobacteria. Cg1421 is a
putative dinucleotide-binding enzyme that has some
similarity with coenzyme F420-dependent NADP oxidore-
ductases. Cg3195 is annotated as a flavin-containing
monooxygenase and has, like Cg1421, a NAD(P) binding
domain. As many MSH-dependent detoxification reac-
tions require NAD or NADP as cofactors [3], Cg1421 and
Cg3195 may be involved in cofactor supply or regener-
ation for these processes. The operon cg0534 to cg0533
encodes a putative integral membrane protein of the YphA
family and menE, an O-succinylbenzoic acid-CoA ligase.
Although the functions of the target genes besides ino1
are largely unknown, there are some clear links to cell wall
synthesis and regulation, and likely also to MSH-
associated reactions. Thus, our analysis of the IpsA regulon
has revealed several novel and interesting targets for further
studies.
Among the target genes of IpsA are not only activated
but also repressed genes. The localization of the IpsA
binding site in the particular promoter regions matches
very well with the type of regulation (Additional file 1:
Figure S5). For the activated genes (cg3323, cg0044,
cg3210, and cg3195) IpsA binding sites are located up-
stream of the -35 region. In the promoters of the repressed
genes (cg1421 and cg0534) the IpsA binding sites overlap
with the -35 and/or the -10 region. This is a furtherindication that the altered mRNA level we see in the DNA
microarrays is a direct effect of the IpsA deletion.
The structure-function relationship of IpsA is compar-
able to other members of the LacI family of transcriptional
regulators. They all contain a DNA-binding domain at the
N-terminus of the protein, composed of three α-helices
that form a helix-turn-helix motif that binds to the major
groove of the operator. The tetramerization of LacI takes
place at the C-terminus, at residues 340 to 357, (Additional
file 1: Figure S12) [32]. These residues are missing in IpsA,
which is in agreement with our gel filtration analysis that
indicated a dimeric conformation for IpsA. A computa-
tional analysis of many LacI regulators and binding sites
revealed a highly conserved hydrophobic amino acid at
position 54 (mostly leucine, L64 in IpsA), which inserts
into a conserved, central CG group in the operator. This
group is present in both binding motifs of the ino1 pro-
moter in C. glutamicum [33].
The formation of 1D-myo-inositol-3-phosphate from
glucose-6-phosphate by Ino1 represents the first step of
PI synthesis; it provides the scaffold on which cell wall
components such as PIMs, LM and LAM are built. Our
chromatographic analysis of radiolabelled polar lipid
extracts of the mutant C. glutamicum ΔipsA grown in
minimal media with glucose generated a characteristic
phenotype, namely that the mutant strain was deficient
in AcPIM2 and PI while Gl-A and Gl-X were unaffected.
In addition, the mutant strain grown on minimal media
supplemented with glucose failed to produce PI-based
LAM. Instead, the GL-X-based LM, Cg-LM-B was
apparent on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis of lipoglycans,
which could explain why C. glutamicum ΔipsA can grow
over several cultivations without supplementation with
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teria. The polar lipid and lipoglycan extracts from the
complemented strain C. glutamicum ΔipsA::pK18-ipsA
grown on minimal media supplemented with glucose
displayed normal levels of AcPIM2, PI, LM and LAM
biosynthesis, with profiles identical to wild-type. These
data are consistent with the view that IpsA affects an
early stage of PI biosynthesis, namely the expression of
ino1. In fact, the polar lipid and lipoglycan extracts ob-
tained from ΔipsA complemented with plasmid-encoded
ino1 also displayed lipid profiles identical to that of the
wild-type, indicating involvement of IpsA in transcrip-
tional activation of ino1 expression. The results imply
that in absence of IpsA, PI-based PIMs, LM and LAM
are not synthesized as the mutant strain no longer pro-
duces the inositol monophosphate synthase required for
synthesis of myo-inositol, a substrate for PI production.
The polar lipid extracts of C. glutamicum ΔipsA comple-
mented with the homolog from C. diphtheriae exhibited
a profile akin to wild-type. Thus DIP1969 is a functional
equivalent of IpsA and can be designated as transcrip-
tional activator of ino1 (DIP0115) in this pathogenic spe-
cies. For the homolog of Rv3575 the situation is not as
clear as for DIP1969. Although we see a positive effect
on growth and a partial complementation in terms of
mycothiol biosynthesis and morphological phenotype,
no PI derived lipids could be identified on the TLC
results. One possible explanation for this is that most of
the inositol formed is channeled towards mycothiol.
Consequently, a low amount of PI derived lipids might
be formed, sufficient for partial complementation of the
phenotype but still too low for detection by TLC. Fur-
thermore, the differences in M. tuberculosis IpsA struc-
ture, binding affinity and specificity can also be a reason
for the only partial complementation. The fact that we
did observe partial complementation with respect to
most phenotypes tested hints at least to a very similar
function in M. tuberculosis.
Conclusions
In this study, we have characterized the LacI regulator
IpsA as a first regulator of inositol anabolism in the
Corynebacteriales. The findings provide insights into the
regulatory mechanisms involved in processes that have
been identified as promising targets for drug develop-
ment. IpsA itself could be such a target, if a myo-inositol
analog could be developed that blocks activation of ino1;
it is noteworthy that a trehalose analog with a bacterio-
static effect on Mycobacterium aurum has been reported
[34]. Finally, the IpsA regulon delivers a promising start-
ing point for the analysis of further, so far unstudied
players in cell wall synthesis in this important class of
bacteria.Methods
Bacterial strains, plasmids and growth media
The bacterial strains and plasmids used in this study are
listed in Additional file 1: Table S1. The C. glutamicum
type strain ATCC 13032 was used as wild-type. Growth
experiments were performed at 30°C and 1,200 rpm in a
Biolector system (m2p-labs, Baesweiler, Germany) in 48-
well FlowerPlates containing 750 μL CGXII minimal
medium [35] supplemented with 3,4-dihydroxybenzoate
(30 mg/L) and carbon source as indicated. If appropriate,
25 μg/mL kanamycin was added. All cloning was per-
formed in Escherichia coli DH5α cultivated at 37°C in
lysogeny broth (LB, [36]) with 50 μg/L kanamycin.
Recombinant DNA work
Routine methods such as polymerase chain reaction
(PCR), DNA restriction and ligation were performed
using standard protocols [36-38]. The oligonucleotides
used in this study were obtained from Eurofins MWG
Operon (Ebersberg, Germany) and are listed in Add-
itional file 1: Table S2. DNA sequencing was performed
by Eurofins MWG Operon (Ebersberg, Germany). The
ΔipsA mutant of C. glutamicum was constructed via a
two-step homologous recombination protocol as described
previously [39]. For further details regarding plasmid and
mutant construction, see Additional file 1.
DNA microarrays
For transcriptome analysis, C. glutamicum wild-type and
ΔipsA cells were grown in 5 mL BHI (brain-heart infusion,
Becton, Dickinson and Company, Le Pont de Claix,
France) for about 6 h at 30°C. A second precultivation was
performed in CGXII minimal medium containing 2% (w/v)
glucose as carbon source. The main cultures were inocu-
lated to an OD of 0.5 in CGXII minimal medium with 2%
(w/v) glucose. At an OD of 5 the cells were harvested by
centrifugation (4,120 g, 10 minutes and 4°C). The cell pellet
was subsequently frozen in liquid nitrogen and stored at
-70°C. The preparation of total RNA was performed as
described previously with the RNeasy Kit from Qiagen
(Hilden, Germany) [40]. Synthesis of fluorescently-labeled
cDNA was carried out as described in [40,41]. Purified
cDNA samples to be compared were pooled and the
prepared two-color samples were hybridized at 65°C
while rotating for 17 h using Agilent’s Gene Expression
Hybridization Kit (Agilent, Böbligen, Germany), hybridization
oven and hybridization chamber. After hybridization, the
arrays were washed using Agilent’s Wash Buffer Kit
according to the manufacturer’s instructions. Fluorescence
of hybridized DNAmicroarrays was determined at 532 nm
(Cy3) and 635 nm (Cy5) at 5 μm resolution with a GenePix
4000B laser scanner and GenePix Pro 6.0 software
(Molecular Devices, Sunnyvale, CA, USA). Fluorescence
images were saved to raw data files in TIFF format (Gene
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out using GenePix image analysis software and results were
saved as GPR-file (GenePix Pro 6.0). For background
correction of spot intensities, ratio calculation and ratio
normalization, GPR-files were processed using the Bio
Conductor R-packages limma and marray [42]. Array data
were deposited in the GEO database [43] under accession
number GSE50210.
Overproduction and purification of IpsA
E. coli BL21(DE3) carrying the expression plasmids
pET-TEV-ipsA or pAN6-ipsA-STREP were grown in LB
medium at 37°C and 120 rpm. IpsA overproduction was in-
duced by addition of 50 μM isopropyl β-D-1-thiogalactopy-
ranoside (IPTG) followed by cultivation at 16°C for 20 h
before the cells were harvested by centrifugation. Nickel
chelate and StrepTactin affinity chromatography were per-
formed as described previously [44,45]. For further purifica-
tion and determination of the molecular weight, gel
filtration was performed using a Superdex™ 200 10/300 GL
column (GE Healthcare, Munich, Germany) (buffer:
50 mM Tris-HCl pH 8, 250 mM NaCl, 1 mM dithiothreitol
(DTT)). Note that the IpsA-variant with the C-terminal
STREP-tag formed less aggregates than the variant with the
His10-tag and eluted at a volume corresponding to 79 kDa,
suggesting dimer formation (Additional file 1: Figure S2).
The protein was concentrated, flash frozen in liquid
nitrogen and stored in the gel filtration buffer at -70°C.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were performed as described previously with the
following modifications [46]. Unless otherwise stated,
the STREP-tag variant was used for the EMSAs. Purified
IpsA was incubated with DNA fragments (30 to 500 bp,
final concentration 0.028 to 1 μM) in binding buffer
(50 mM Tris-HCl pH 7.5, 40 mM KCl, 5 mM MgCl2) in
a total volume of 10 μL. Electrophoresis was performed
with 10% to 15% native polyacrylamide gels at room
temperature and 150 or 180 V for 45 to 60 minutes
(depending on the size of the DNA fragments). For the
testing of effector molecules, IpsA was first incubated
with the putative effector for 20 minutes at room
temperature, followed by addition of the DNA, further 20
minutes incubation and electrophoresis as described above.
As control AcnR protein and the acn promoter fragment
was used as described in [47] (Additional file 1: Figure S7).
Fluorescence microscopy
For recording fluorescence microscopy images, cells were
centrifuged and resuspended in phosphate-buffered saline
(PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4,
1.4 mM KH2PO4, pH 7.3) containing 200 ng/mL DAPI
and 300 ng/mL nile red. After 5 to 10 minutes incubation
at room temperature, the cells were analyzed on agar padsusing a Zeiss Axioplan 2 imaging microscope that was
equipped with an AxioCam MRm camera and a Plan-
Apochromat 100×, 1.40 Oil DIC oil-immersion objective.
Digital images were acquired and analyzed with AxioVision
4.6 software (Zeiss, Göttingen, Germany).
Promoter fusion studies
To analyze the regulation of the ino1 promoter by IpsA
in vivo, a DNA fragment covering the cg3323 promoter
region was fused to the eyfp-coding sequence (pJC1-
Pcg3323-eYFP). Wild-type and ΔipsA cells were trans-
formed with the resulting plasmid and the fluorescence
output was analyzed on minimal medium with 2% (w/v)
glucose or myo-inositol in the Biolector system.
Extraction and determination of mycothiol
The determination of mycothiol was carried out as de-
scribed [21]. Briefly, cells were first cultivated in BHI
medium for 6 h and then twice in CGXII minimal medium
with 4% (w/v) as carbon source at 30°C and 120 rpm for
16 h and 24 h, respectively. 200 mg of wet cells were resus-
pended in 1 mL of warm (60°C) acetonitrile containing
20 mM Tris-HCl, pH 8.0 and 2 mM bromobimane
(Sigma-Aldrich, Taufkirchen near Munich, Germany), soni-
ficated for 20 s and further incubated in a 60°C water bath
for 15 minutes in the dark. The samples were acidified with
5 μL of 5 M methanesulfonic acid and the cellular debris
was removed by centrifugation at 16,000 g for 10 minutes.
The supernatants were filtered and diluted fivefold in
10 mM methanesulfonic acid. A wild-type control sample
was incubated with 5 mM NMM to block the thiol groups
prior to derivatization with bromobimane. The sample
were analyzed using a C18 column (LiChrospher RP 18,
125 × 4 mm) and the solvents A (100 mM sodium acetate
buffer pH 7.2) and B (100% methanol) a flow rate of
0.7 mL/minute and the following gradient: 0 minutes, 15%
B; 1 minute, 15% B; 1.5 minutes, 35% B; 11 minutes, 80%
B; 12 minutes, 95% B; 13 minutes 100% B. The peak
assumed to be mycothiol (5.61 minutes) was identified by
comparison of the wild-type chromatogram with the one
from the ΔmshC strain and the NMM treated sample. Fur-
thermore this peak appears shortly after glutathione (5.14)
as published for a similar method [48].
Growth of bacteria for lipid and lipoglycan analysis
Overnight cultures of C. glutamicum ATCC 13032, C.
glutamicum ΔipsA, C. glutamicum ΔipsA::pK18int-ipsA,
and C. glutamicum ΔipsA harboring ino1 (cg3323),
Rv3575 and DIP1969 in plasmid pAN6 were pregrown in
20 mL of 3.7% brain-heart-glucose bouillon (Sigma-
Aldrich, Gillingham, UK) containing Kanamycin (25 μg/
mL). The cells were washed once with PBS, used to inocu-
late a second preculture to an OD600 of 1 in 50 mL CGXII
minimal medium (50 mL) supplemented with 2% glucose
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cells of the second preculture were washed once with PBS
and used to inoculate the main cultures to an OD600 of 0.1
in 10 mL CGXII minimal medium (10 mL), supplemented
with either 2% glucose or 2% myo-inositol and grown until
early log phase. At early log phase, the cells were labeled
with 1 μCi/mL [1,2-14C]-acetate (1.66 to 2.22GBq/mmol,
PerkinElmer Inc., Waltham, Massachusetts, USA) and
incubated overnight at 30°C with gentle shaking. The cells
were recovered following centrifugation at 3,500 g and dried.
Analysis of polar lipids and lipoglycans
The cell cultivation procedure for the following experi-
ments is described in the Additional file 1. Polar and apolar
lipid extracts were prepared from the dried cell pellets
using established procedures [49]. The dried polar lipid
extracts were resuspended in CHCl3:CH3OH (100 μL, 2: 1,
v/v) and the incorporation of [1,2-14C] acetate in lipid ex-
tracts determined by counting an aliquot (5%) using scintil-
lation fluid (5 mL). To analyze the lipid profiles, equal
counts of polar lipid extracts (20,000 cpm) were applied to
silica thin layer chromatography (silica gel 60 F254 Merck
5554, TLC plates) and developed using the solvent system:
CHCl3:CH3OH:H2O (60:30:6, v/v/v) in the first dimension
and CHCl3:CH3CO2H:CH3OH:H2O (40:25:3:6, v/v/v/v) in
the second dimension. The autoradiograms were obtained
by exposing the TLC results to X-ray films (Kodak-Biomax
MR Kodak, Rochester, New York, USA) for 48 h.
Lipoglycans were extracted using previously described
protocols [50]. Briefly, dried cell pellets from a 10 mL
volume culture were resuspended in water and refluxed
five times with equal volume of 50% aqueous C2H5OH at
85°C, for 6 h intervals. The suspension was centrifuged
and the supernatant recovered between each extraction
following centrifugation. The combined supernatant frac-
tions were dried and subjected to hot phenol-H2O treatment
at 65°C. The aqueous phase containing the crude lipoglycan
fraction was recovered and dialyzed (molecular weight cut-
off 3.5 KDa) against water. The dialyzed fraction was dried
and 20 μg of lipoglycans loaded on a 15% SDS-PAGE gel.
The lipoglycans were visualized using Pro-Q emerald
glycoprotein stain (Life Technologies, Darmstadt, Germany).
Additional file
Additional file 1: Additional methods, figures and tables.
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